RxDoctor Payments Data

Javier Saenz, MD

Family Medicine · la Joya, TXNPI 1770781452

Payments from drug & device makers

$46,921in general payments, 2019–2025

Across 45 payments — averaging $1042.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$25K
  • Boehringer Ingelheim Pharma GmbH & Co.kg$20K
  • Boehringer Ingelheim France S.a.s.$1K
  • Johnson & Johnson$168
  • Novo Nordisk$142
  • Lilly USA, LLC$100
  • plus $277 from 9 others

What the payments were for

  • Food & beverage$702100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$46,921 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$216,196
Medicare patients
171
Services billed
5,434

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin650$576,555
JanuviaSitagliptin Phosphate386$316,151
OzempicSemaglutide219$255,091
MounjaroTirzepatide147$202,002
LinzessLinaclotide281$181,644
TradjentaLinagliptin265$174,346
TrulicityDulaglutide108$130,892
FarxigaDapagliflozin Propanediol120$94,797
RybelsusSemaglutide72$91,099
MyrbetriqMirabegron158$83,887
XareltoRivaroxaban83$64,382
EliquisApixaban62$52,013
Tresiba Flextouch U-100Insulin Degludec87$48,214
Tresiba Flextouch U-200Insulin Degludec62$44,237
EntrestoSacubitril/Valsartan38$40,258

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Synjardy$25,362$760,756926 claims
Novo NordiskOzempic, Rybelsus$142$346,190291 claims
Lilly USA, LLCMounjaro, Trulicity$100$332,894255 claims
AbbVieLinzess, Restasis$80$190,090295 claims
AstraZenecaFarxiga$14$94,797120 claims
Johnson & JohnsonXarelto$168$64,38283 claims
PfizerEliquis$28$52,01362 claims
GSKTrelegy Ellipta, Breo Ellipta$18$41,28778 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.

Other family medicine in la Joya

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →